Steve Evans

Steve Evans is currently the CEO and Acting Chair at Oncolyze, an early-stage oncology biotech company. Steve also has experience as the CEO at Althera. At Oncolyze, Steve is leading the development of their lead drug candidate, OM-301, which has a unique mechanism of action targeting cancer cells.